Actionable news
0
All posts from Actionable news
Actionable news in GLMD: GALMED PHARMACEUTICALS Ltd.,

Galmed Pharmaceuticals to Present at International Liver Congress Data that Shows Aramchol™ has a Potential Direct Effect on Liver Fibrosis

TEL AVIV, Israel, April 5, 2017 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH, and other liver diseases, announced today that it will present data at the 53rd Annual Meeting of the European Association for the Study of the Liver (EASL) during the International Liver Congress (ILC) 2017. The congress is being held in Amsterdam, Holland during April 19-23, 2017.

Galmed's presentations report the efficacy of Aramchol in MCD NASH and TAA fibrosis models. TAA animal model is the gold standard to demonstrate direct anti-fibrotic effect. The data suggest a dual effect of Aramchol on fibrosis via down regulation of the sequence of events, from steatosis to fibrosis and an improvement of Fatty Acid oxidation as well a direct impact on collagen producing cells which results in reversing fibrosis.

The presentations will include:

  • Friday, April 21, 2017, 08:00-18:00

    Aramchol™ reduces established fibrosis in MCD diet animal model

    Speaker: Prof. José M. Mato
  • Saturday, April 22, 2017, 08:00-18:00

    Noninvasive serum biomarkers reflect the effect of Aramchol™ on mice fibrotic livers

    Speaker: Prof. José M. Mato
  • Saturday, April 22, 2017, 08:00-18:00

    The anti-fibrotic effect of Aramchol™ on liver Fibrosis in TAA animal model

    Speaker: Prof. Shimon Reif

For more information please visit the EASL online programme for posters: https://events.easl.eu/EventProgramme/ILC2017/POSTER.aspx

Workshop on Saturday, April 22, 2017, 07:30-08:30am

"NASH fibrosis - from Pathology to Treatment", chair by Arun Sanyal

Presentations:

07:30-07:50: The pathogenesis of NASH - Insights into potential targets for treatment of steatosis, inflammation and fibrosis, Speaker: Prof. Vlad Ratziu, MD, PhD (France)

07:50-08:10: Aramchol - Treating NASH through prevention and reversal of fibrosis, Speakers: Prof. José M. Mato (Spain) and Prof. Shimon Reif...


More